Shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) have earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $46.25.

Several research firms have commented on ENTA. Royal Bank Of Canada began coverage on Enanta Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating for the company. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. JMP Securities increased their target price on Enanta Pharmaceuticals from $40.00 to $53.00 in a research report on Wednesday, October 4th. Finally, BidaskClub upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, August 11th.

Enanta Pharmaceuticals (NASDAQ:ENTA) traded down $0.15 during trading on Friday, reaching $47.80. The company’s stock had a trading volume of 154,200 shares, compared to its average volume of 194,440. The company has a market capitalization of $915.38, a P/E ratio of 54.49 and a beta of 0.64. Enanta Pharmaceuticals has a 1 year low of $25.92 and a 1 year high of $51.33.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing the consensus estimate of $2.13 by ($0.27). The firm had revenue of $75.93 million during the quarter, compared to the consensus estimate of $73.80 million. Enanta Pharmaceuticals had a net margin of 17.23% and a return on equity of 6.46%. Enanta Pharmaceuticals’s revenue for the quarter was up 491.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.09) earnings per share. sell-side analysts anticipate that Enanta Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Several hedge funds have recently modified their holdings of the company. Texas Permanent School Fund increased its stake in shares of Enanta Pharmaceuticals by 0.8% in the second quarter. Texas Permanent School Fund now owns 10,146 shares of the biotechnology company’s stock valued at $365,000 after buying an additional 85 shares during the period. Municipal Employees Retirement System of Michigan increased its stake in shares of Enanta Pharmaceuticals by 3.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 110 shares during the period. SG Americas Securities LLC increased its stake in shares of Enanta Pharmaceuticals by 5.8% in the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 237 shares during the period. Schwab Charles Investment Management Inc. increased its stake in shares of Enanta Pharmaceuticals by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 53,616 shares of the biotechnology company’s stock valued at $1,930,000 after buying an additional 304 shares during the period. Finally, Thrivent Financial For Lutherans increased its stake in shares of Enanta Pharmaceuticals by 7.3% in the second quarter. Thrivent Financial For Lutherans now owns 8,410 shares of the biotechnology company’s stock valued at $303,000 after buying an additional 570 shares during the period. 66.97% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/08/enanta-pharmaceuticals-inc-enta-receives-average-rating-of-buy-from-analysts.html.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings for Enanta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.